Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS

Classement en actions #17276
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Prix de l'action
$8.16
Dernière synchronisation: 2025-06-26
Capitalisation boursière
$234.57M
Changement (1 jour)
0.00%
Changement (1 an)
-88.86%
Pays
US
Échange Regulus Therapeutics Inc. (RGLS)

Catégorie

Healthcare
Historique du prix de l'action pour Regulus Therapeutics Inc. (RGLS)
Prix de clôture le plus élevé : $73.27 le 2024-11-01

Prix de clôture le plus bas : $21.00 le 2010-04-01
Historique du prix de l'action de Regulus Therapeutics Inc. de 2010 à 2026
Performance annuelle du prix de l'action
Année Performance
2024 113.53%
2023 140.97%
2022 -61.38%
2021 -67.58%
2020 -13.91%
2019 22.71%
2018 12.94%
2017 104.37%
2016 -25.20%
2015 -38.37%
2014 34.13%
2013 93.41%
2012 67.05%
2011 2.83%
2010 0.00%
Prix de l'action pour des entreprises similaires ou concurrentes
Entreprise Prix de l'action Variation 1a% Pays
$527.18 23.62%
US
$251.29 835.90%
US
$137.19 -4.22%
AU
$890.85 9.42%
NL
$752.87 7.01%
CH